Daily Archives: December 6, 2017

CMS assigns permanent J-code for Savients KRYSTEXXA to take care of RCG Savient Pharmaceuticals.

CMS assigns permanent J-code for Savient’s KRYSTEXXA to take care of RCG Savient Pharmaceuticals, Inc. The new J-code, J2507, was designated by the Centers for Medicare and Medicaid Providers and can help simplify the billing and reimbursement procedure for prescribers of KRYSTEXXA, the first and just U.S. Food and Drug Administration approved treatment for refractory chronic gout . The option of a long lasting J-code for KRYSTEXXA is a significant step toward making certain healthcare suppliers and their patients with severe and debilitating gout, or RCG, have access to the only and first product for RCG, said John H. Continue reading